Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloi...(ons. Forward-looking statements involve ...),Health

Date:11/5/2009

ons. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for additional funding, the risk that Sunesis' drug development activities for voreloxin could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials, risks related to the manufacturing of voreloxin, and the risk that Sunesis' proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Investor and Media Inquiries:
    Andrea Rabney               Eric Bjerkholt
    Argot Partners              Sunesis Pharmaceuticals
    212-600-1902                650-266-3717

SOURCE Sunesis Pharmaceuticals, Inc.

'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association